p16 as a biomarker to distinguish atypical ductal hyperplasia from ductal carcinoma in situ and to predict breast cancer progression

Authors

• Judy A. Tjoe, Advocate Aurora HealthFollow
• Brittany S. Last, Advocate Aurora HealthFollow
• Jun Yin, Advocate Aurora HealthFollow

Recommended Citation

Tjoe J, Last B, Yin J. p16 as a biomarker to distinguish atypical ductal hyperplasia from ductal carcinoma in situ and to predict breast cancer progression. Ann Surg Oncol 2019;26(2 Suppl):53. doi: 10.1245/s10434-019-07407-7.

Affiliations

Advocate Aurora Health

Aurora Research Institute

Document Type

Abstract